Conversely, in patients with idiopathic pulmonary fibrosis receiving the tyrosine kinase inhibitor nintedanib, there was a significant inverse correlation between the plasma AT-III level and pulmonary function test parameters, with high baseline plasma AT-III levels being a predictor of poor prognosis. This evidence concerns the gene SERPINC1 and pulmonary fibrosis.